# Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI

Study · id `cardio:ct-nct01313572` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01313572](<https://clinicaltrials.gov/study/NCT01313572>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01313572

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 197 participants.

## Technical summary

Registry record NCT01313572. Randomized; triple masking; primary purpose diagnostic. Start 2011-08 (registry gives no type); primary completion 2012-04 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose diagnostic
- Phase: Phase 3
- Enrolled: 197 participants (enrolled count; ClinicalTrials.gov record NCT01313572, source copy `cardio:ctgov-nct01313572-2012-05-01`, retrieved 2026-10-26)
- Start date: 2011-08 (registry gives no type) (ClinicalTrials.gov record NCT01313572, source copy `cardio:ctgov-nct01313572-2012-05-01`, retrieved 2026-10-26)
- Primary completion: 2012-04 (actual) (ClinicalTrials.gov record NCT01313572, source copy `cardio:ctgov-nct01313572-2012-05-01`, retrieved 2026-10-26)
- Completion: 2012-04 (actual) (ClinicalTrials.gov record NCT01313572, source copy `cardio:ctgov-nct01313572-2012-05-01`, retrieved 2026-10-26)
- Countries: United States; Argentina; Belgium; Brazil; Netherlands (ClinicalTrials.gov record NCT01313572, source copy `cardio:ctgov-nct01313572-2012-05-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01313572-2012-05-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI
- Acronym: ASPECT2
- Condition: Coronary Artery Disease
- Intervention (Drug): Apadenoson SPECT-MPI
- Intervention (Drug): Adenosine SPECT-MPI
- Lead sponsor: Forest Laboratories
- Lead sponsor class: INDUSTRY
- Collaborator: PPD Development, LP
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Forest Laboratories (`cardio:org-forest-laboratories`)
- Registry lists this organization as a collaborator: PPD Development, LP (`cardio:org-ppd-development-lp`)

## Provenance

Content hash: 7247652d64087c943c40ffe557bb2d521df2cdbf7cef162dd1b97e5f89ff0015
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
